Boxes of Ozempic and Wegovy, produced by Novo Nordisk, can be found in pharmacies.
Holly Adams | Reuters
Shares of Danish pharmaceutical giant Novo Nordisk Shares plummeted more than 24% on Friday after late-stage trial results for the company’s experimental weight-loss drug CagriSema failed to meet expectations, and were expected to post their worst one-day drop ever.
The maker of the popular Wegovy obesity drug says its new drug candidate helped patients lose 22.7% of their body weight, down from 25% have predictionsReuters reports.
The stock fell 22% as of 11:24 a.m. London time.
This is a breaking news story. Please check back for updates.
About The Author
